Circulating TNF receptor levels are associated with estimated glomerular filtration rate even in healthy individuals with normal kidney function.

Biomarker Diabetes Healthy subject Kidney function TNF receptor eGFR

Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
27 Mar 2024
Historique:
received: 18 08 2023
accepted: 15 03 2024
medline: 28 3 2024
pubmed: 28 3 2024
entrez: 28 3 2024
Statut: epublish

Résumé

The association between serum tumor necrosis factor receptor (TNFRs: TNFR1, TNFR2) levels and estimated glomerular filtration rate (eGFR) observed in patients with diabetes has not been comprehensively tested in healthy subjects with normal kidney function. It also remains unclear whether TNFR levels differ by age and sex, and between healthy subjects and diabetics. We measured serum TNFR levels in 413 healthy subjects and 292 patients with type 2 diabetes. In healthy subjects, TNFR levels did not differ between men and women. Additionally, TNFR2, but not TNFR1, levels increased with age. In multivariate analysis, TNFR1 was associated only with cystatin C-based eGFR (eGFR-CysC), whereas TNFR2 was associated with systolic blood pressure in addition to eGFR-CysC. Both TNFRs were associated with lower eGFR (eGFR-Cys < 90 mL/min/1.73 m

Identifiants

pubmed: 38538662
doi: 10.1038/s41598-024-57265-x
pii: 10.1038/s41598-024-57265-x
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

7245

Subventions

Organisme : JSPS KAKENHI
ID : JP20K08617

Informations de copyright

© 2024. The Author(s).

Références

Tomino, Y. & Gohda, T. The prevalence and management of diabetic nephropathy in Asia. Kidney Dis. 1, 52–60. https://doi.org/10.1159/000381757 (2015).
doi: 10.1159/000381757
Gohda, T. et al. Concept of diabetic kidney disease: Paradigm shift from albuminuria-based to GFR-based kidney disease. Juntendo Med. J. 65, 510–516. https://doi.org/10.14789/jmj.2019.65.JMJ19-R16 (2019).
doi: 10.14789/jmj.2019.65.JMJ19-R16
Gohda, T. & Tomino, Y. Novel biomarkers for the progression of diabetic nephropathy: soluble TNF receptors. Curr. Diab. Rep. 13, 560–566. https://doi.org/10.1007/s11892-013-0385-9 (2013).
doi: 10.1007/s11892-013-0385-9 pubmed: 23657763
Murakoshi, M., Gohda, T. & Suzuki, Y. Circulating tumor necrosis factor receptors: A potential biomarker for the progression of diabetic kidney disease. Int. J. Mol. Sci. 21, 1957. https://doi.org/10.3390/ijms21061957 (2020).
doi: 10.3390/ijms21061957 pubmed: 32183005 pmcid: 7139523
Niewczas, M. A. et al. Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. J. Am. Soc. Nephrol. 23, 507–515. https://doi.org/10.1681/ASN.2011060627 (2012).
doi: 10.1681/ASN.2011060627 pubmed: 22266663 pmcid: 3294310
Gohda, T. et al. Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. J. Am. Soc. Nephrol. 23, 516–524. https://doi.org/10.1681/ASN.2011060628 (2012).
doi: 10.1681/ASN.2011060628 pubmed: 22266664 pmcid: 3294299
Bhatraju, P. K., Zelnick, L. R., Shlipak, M., Katz, R. & Kestenbaum, B. Association of soluble TNFR-1 concentrations with long-term decline in kidney function: The multi-ethnic study of atherosclerosis. J. Am. Soc. Nephrol. 29, 2713–2721. https://doi.org/10.1681/ASN.2018070719 (2018).
doi: 10.1681/ASN.2018070719 pubmed: 30287518 pmcid: 6218870
Gohda, T. et al. Association between kidney function decline and baseline TNFR levels or change ratio in TNFR by febuxostat chiefly in non-diabetic CKD patients with asymptomatic hyperuricemia. Front. Med. 8, 634932. https://doi.org/10.3389/fmed.2021.634932 (2021).
doi: 10.3389/fmed.2021.634932
Sarnak, M. J. et al. Plasma biomarkers as risk factors for incident CKD. Kidney Int. Rep. 7, 1493–1501. https://doi.org/10.1016/j.ekir.2022.03.018 (2022).
doi: 10.1016/j.ekir.2022.03.018 pubmed: 35812266 pmcid: 9263237
Murakoshi, M. et al. Progranulin and its receptor predict kidney function decline in patients with type 2 diabetes. Front. Endocrinol. 13, 849457. https://doi.org/10.3389/fendo.2022.849457 (2022).
doi: 10.3389/fendo.2022.849457
Murakoshi, M. et al. Circulating tumor necrosis factor-related biomarkers predict kidney function decline in Japanese patients with diabetes: An observational cohort study. Diabetes Res. Clin. Pract. 206, 111017. https://doi.org/10.1016/j.diabres.2023.111017 (2023).
doi: 10.1016/j.diabres.2023.111017 pubmed: 37972856
Kamei, N. et al. Association between circulating tumor necrosis factor-related biomarkers and estimated glomerular filtration rate in type 2 diabetes. Sci. Rep.-Uk 8, 15302. https://doi.org/10.1038/s41598-018-33590-w (2018).
doi: 10.1038/s41598-018-33590-w
Gohda, T. et al. Clinical predictive biomarkers for normoalbuminuric diabetic kidney disease. Diabetes Res. Clin. Pract. 141, 62–68. https://doi.org/10.1016/j.diabres.2018.04.026 (2018).
doi: 10.1016/j.diabres.2018.04.026 pubmed: 29729375
Dzienis-Straczkowska, S. et al. Soluble tumor necrosis factor-alpha receptors in young obese subjects with normal and impaired glucose tolerance. Diabetes Care 26, 875–880. https://doi.org/10.2337/diacare.26.3.875 (2003).
doi: 10.2337/diacare.26.3.875 pubmed: 12610052
Miyazawa, I. et al. Association between serum soluble TNFalpha receptors and renal dysfunction in type 2 diabetic patients without proteinuria. Diabetes Res. Clin. Pract. 92, 174–180. https://doi.org/10.1016/j.diabres.2011.01.008 (2011).
doi: 10.1016/j.diabres.2011.01.008 pubmed: 21288590
Matsuo, S. et al. Revised equations for estimated GFR from serum creatinine in Japan. Am. J. Kidney Dis. 53, 982–992. https://doi.org/10.1053/j.ajkd.2008.12.034 (2009).
doi: 10.1053/j.ajkd.2008.12.034 pubmed: 19339088
Horio, M., Imai, E., Yasuda, Y., Watanabe, T. & Matsuo, S. GFR estimation using standardized serum cystatin C in Japan. Am. J. Kidney Dis. 61, 197–203. https://doi.org/10.1053/j.ajkd.2012.07.007 (2013).
doi: 10.1053/j.ajkd.2012.07.007 pubmed: 22892396
Gohda, T. et al. Circulating TNF receptors 1 and 2 Predict mortality in patients with end-stage renal disease undergoing dialysis. Sci. Rep. 7, 43520. https://doi.org/10.1038/srep43520 (2017).
doi: 10.1038/srep43520 pubmed: 28256549 pmcid: 5335256
Gohda, T. et al. Fractional excretion of tumor necrosis factor receptor 1 and 2 in patients with type 2 diabetes and normal renal function. J. Diabetes Investig. 12, 382–389. https://doi.org/10.1111/jdi.13351 (2021).
doi: 10.1111/jdi.13351 pubmed: 32643269
Franceschi, C. et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann. N. Y. Acad. Sci. 908, 244–254. https://doi.org/10.1111/j.1749-6632.2000.tb06651.x (2000).
doi: 10.1111/j.1749-6632.2000.tb06651.x pubmed: 10911963
Shaw, A. C., Goldstein, D. R. & Montgomery, R. R. Age-dependent dysregulation of innate immunity. Nat. Rev. Immunol. 13, 875–887. https://doi.org/10.1038/nri3547 (2013).
doi: 10.1038/nri3547 pubmed: 24157572 pmcid: 4096436
Sen, T. et al. Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial. Diabetologia 64, 2147–2158. https://doi.org/10.1007/s00125-021-05512-5 (2021).
doi: 10.1007/s00125-021-05512-5 pubmed: 34415356 pmcid: 8423682
Waijer, S. W. et al. Association between TNF receptors and KIM-1 with kidney outcomes in early-stage diabetic kidney disease. Clin. J. Am. Soc. Nephrol. 17, 251–259. https://doi.org/10.2215/CJN.08780621 (2022).
doi: 10.2215/CJN.08780621 pubmed: 34876454 pmcid: 8823939
Pavkov, M. E. et al. Tumor necrosis factor receptors 1 and 2 are associated with early glomerular lesions in type 2 diabetes. Kidney Int. 89, 226–234. https://doi.org/10.1038/ki.2015.278 (2016).
doi: 10.1038/ki.2015.278 pubmed: 26398493 pmcid: 4805514
Chen, T. K. et al. Longitudinal TNFR1 and TNFR2 and kidney outcomes: Results from AASK and VA NEPHRON-D. J. Am. Soc. Nephrol. 33, 996–1010. https://doi.org/10.1681/ASN.2021060735 (2022).
doi: 10.1681/ASN.2021060735 pubmed: 35314457 pmcid: 9063900
Niewczas, M. A. et al. A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes. Nat. Med. 25, 805–813. https://doi.org/10.1038/s41591-019-0415-5 (2019).
doi: 10.1038/s41591-019-0415-5 pubmed: 31011203 pmcid: 6508971
Hotamisligil, G. S., Arner, P., Atkinson, R. L. & Spiegelman, B. M. Differential regulation of the p80 tumor necrosis factor receptor in human obesity and insulin resistance. Diabetes 46, 451–455. https://doi.org/10.2337/diab.46.3.451 (1997).
doi: 10.2337/diab.46.3.451 pubmed: 9032102
Saulnier, P. J. et al. Association of circulating biomarkers (Adrenomedullin, TNFR1, and NT-proBNP) with renal function decline in patients with Type 2 diabetes: A French prospective cohort. Diabetes Care 40, 367–374. https://doi.org/10.2337/dc16-1571 (2017).
doi: 10.2337/dc16-1571 pubmed: 27998909
Oshima, M. et al. Comparison of circulating biomarkers in predicting diabetic kidney disease progression with autoantibodies to erythropoietin receptor. Kidney Int. Rep. 6, 284–295. https://doi.org/10.1016/j.ekir.2020.10.039 (2021).
doi: 10.1016/j.ekir.2020.10.039 pubmed: 33615053
Pavkov, M. E. et al. Elevation of circulating TNF receptors 1 and 2 increases the risk of end-stage renal disease in American Indians with type 2 diabetes. Kidney Int. 87, 812–819. https://doi.org/10.1038/ki.2014.330 (2015).
doi: 10.1038/ki.2014.330 pubmed: 25272234

Auteurs

Tomohito Gohda (T)

Department of Nephrology, Juntendo University Faculty of Medicine, Hongo 2-1-1, Bunkyo-Ku, Tokyo, 113-8421, Japan. goda@juntendo.ac.jp.

Maki Murakoshi (M)

Department of Nephrology, Juntendo University Faculty of Medicine, Hongo 2-1-1, Bunkyo-Ku, Tokyo, 113-8421, Japan.

Terumi Shibata (T)

Department of Nephrology, Juntendo University Faculty of Medicine, Hongo 2-1-1, Bunkyo-Ku, Tokyo, 113-8421, Japan.

Yusuke Suzuki (Y)

Department of Nephrology, Juntendo University Faculty of Medicine, Hongo 2-1-1, Bunkyo-Ku, Tokyo, 113-8421, Japan.

Hiroyuki Takemura (H)

Department of Clinical Laboratory, Juntendo University Hospital, Bunkyo-Ku, Tokyo, Japan.

Koji Tsuchiya (K)

Department of Clinical Laboratory, Juntendo University Hospital, Bunkyo-Ku, Tokyo, Japan.

Tomoki Okada (T)

Department of Clinical Laboratory, Juntendo University Hospital, Bunkyo-Ku, Tokyo, Japan.

Mitsuru Wakita (M)

Department of Clinical Laboratory, Juntendo University Hospital, Bunkyo-Ku, Tokyo, Japan.

Yuki Horiuchi (Y)

Department of Clinical Laboratory Medicine, Juntendo University Faculty of Medicine, Bunkyo-Ku, Tokyo, Japan.

Yoko Tabe (Y)

Department of Clinical Laboratory Medicine, Juntendo University Faculty of Medicine, Bunkyo-Ku, Tokyo, Japan.

Nozomu Kamei (N)

Department of Endocrinology and Metabolism, Hiroshima Red Cross Hospital & Atomic-Bomb Survivors Hospital, Hiroshima, Japan.
Institute for Clinical Research, National Hospital Organization, Kure Medical Center and Chugoku Cancer Center, Hiroshima, Japan.

Classifications MeSH